Importantly, liver organoids generated from GSD1a patient-derived iPSCs by the new protocol exhibited disease-specific phenotypes, highlighting the potential of these organoids for congenital liver disease modeling and drug screening. This evidence concerns the gene G6PC1 and liver disorder.